Sequoia Capital China has led over $100 million Series B funding round in industrial synthetic biotech firm Bota Biosciences with the participation of new investor CMB International Capital, a Hong Kong-based subsidiary of China Merchants Bank.
The company has also roped in a host of returning investors such as Matrix Partners China, 5Y Capital, Source Code Capital, Sherpa Healthcare Partners, and Meituan, a Chinese conglomerate that runs one of the country’s biggest food delivery platforms called Dianping.
